STERIS (STE) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STE shares.
View STE analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12 month target prices for STERIS's stock. Their STE share price forecasts range from $200.00 to $240.00. On average, they anticipate the company's share price to reach $223.00 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for STE or view top-rated stocks among Wall Street analysts.

STERIS's stock was trading at $184.69 at the start of the year. Since then, STE stock has increased by 8.6% and is now trading at $200.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our STE earnings forecast.

STERIS plc (NYSE:STE) issued its quarterly earnings data on Wednesday, May, 10th. The medical equipment provider reported $2.30 earnings per share for the quarter, topping analysts' consensus estimates of $2.15 by $0.15. The medical equipment provider had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a net margin of 2.16% and a trailing twelve-month return on equity of 13.50%. During the same quarter in the previous year, the business earned $2.04 earnings per share.
Read the conference call transcript.

STERIS announced a quarterly dividend on Wednesday, May 3rd. Stockholders of record on Wednesday, June 14th will be paid a dividend of $0.47 per share on Wednesday, June 28th. This represents a $1.88 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Tuesday, June 13th.
Read our dividend analysis for STE.

ETFs with the largest weight of STERIS (NYSE:STE) stock in their portfolio include VanEck Environmental Services ETF (EVX), VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Indxx Medical Devices ETF (MDEV), Nuveen ESG Mid-Cap Value ETF (NUMV), iShares U.S. Medical Devices ETF (IHI), Invesco S&P 500 Equal Weight Health Care ETF (RYH), BlackRock Future Health ETF (BMED) and SPDR S&P Health Care Equipment ETF (XHE).

STERIS (NYSE:STE) pays an annual dividend of $1.88 per share and currently has a dividend yield of 0.94%. The company has been increasing its dividend for 17 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 175.70%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, STE will have a dividend payout ratio of 19.64% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

STERIS updated its FY 2024 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $8.55-$8.75 for the period, compared to the consensus EPS estimate of $8.75. The company issued revenue guidance of $5.30 billion-$5.35 billion, compared to the consensus revenue estimate of $5.14 billion.

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.74%), WCM Investment Management LLC (5.50%), State Street Corp (4.13%), Price T Rowe Associates Inc. MD (2.30%), Geode Capital Management LLC (2.07%) and Pictet Asset Management SA (1.46%). Insiders that own company stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden and Walter M Rosebrough Jr.
View institutional ownership trends.

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STE stock can currently be purchased for approximately $200.56.

STERIS (NYSE:STE) has a market capitalization of $19.91 billion and generates $4.96 billion in revenue each year. The medical equipment provider earns $107.03 million in net income (profit) each year or $1.07 on an earnings per share basis.

The company employs 16,422 workers across the globe.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The official website for the company is www.steris.com. The medical equipment provider can be reached via phone at (440) 354-2600, via email at julie_winter@steris.com, or via fax at 440-639-4457.